NO313913B1 - IL-8 reseptor antagonister, anvendelse og fremgangsmÕte for fremstilling derav, samt farmasöytisk preparat - Google Patents

IL-8 reseptor antagonister, anvendelse og fremgangsmÕte for fremstilling derav, samt farmasöytisk preparat Download PDF

Info

Publication number: NO313913B1
Authority: NO; Norway
Prior art keywords: compound; formula; dihydro; urea; dioxo
Prior art date: 1997-01-23

Application number

NO19993585A

Other languages

English (en)

Norwegian (no)

Other versions

NO993585D0 (no

NO993585L (no

Inventor

Katherine Louisa Widdowson

Hong Nie

Jr Melvin Clarence Rutledge

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-01-23

Filing date

1999-07-22

Publication date

2002-12-23

1999-07-22 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

1999-07-22 Publication of NO993585D0 publication Critical patent/NO993585D0/no

1999-09-21 Publication of NO993585L publication Critical patent/NO993585L/no

2002-12-23 Publication of NO313913B1 publication Critical patent/NO313913B1/no

Links

238000000034 method Methods 0.000 title claims description 26
238000002360 preparation method Methods 0.000 title claims description 19
239000000825 pharmaceutical preparation Substances 0.000 title claims description 9
108090001007 Interleukin-8 Proteins 0.000 title description 59
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 79
102000019034 Chemokines Human genes 0.000 claims description 23
108010012236 Chemokines Proteins 0.000 claims description 23
201000010099 disease Diseases 0.000 claims description 23
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
230000001404 mediated effect Effects 0.000 claims description 10
150000003839 salts Chemical class 0.000 claims description 10
206010040070 Septic Shock Diseases 0.000 claims description 9
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
229910052736 halogen Inorganic materials 0.000 claims description 7
239000001257 hydrogen Substances 0.000 claims description 7
229910052739 hydrogen Inorganic materials 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 6
150000002367 halogens Chemical class 0.000 claims description 6
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 5
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 5
201000004681 Psoriasis Diseases 0.000 claims description 4
238000006243 chemical reaction Methods 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
150000002828 nitro derivatives Chemical class 0.000 claims description 4
230000002829 reductive effect Effects 0.000 claims description 4
238000007363 ring formation reaction Methods 0.000 claims description 4
208000024827 Alzheimer disease Diseases 0.000 claims description 3
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
206010009900 Colitis ulcerative Diseases 0.000 claims description 3
208000011231 Crohn disease Diseases 0.000 claims description 3
206010012438 Dermatitis atopic Diseases 0.000 claims description 3
206010014824 Endotoxic shock Diseases 0.000 claims description 3
206010018364 Glomerulonephritis Diseases 0.000 claims description 3
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
206010063837 Reperfusion injury Diseases 0.000 claims description 3
206010040047 Sepsis Diseases 0.000 claims description 3
208000006011 Stroke Diseases 0.000 claims description 3
208000007536 Thrombosis Diseases 0.000 claims description 3
206010044248 Toxic shock syndrome Diseases 0.000 claims description 3
231100000650 Toxic shock syndrome Toxicity 0.000 claims description 3
201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
206010003246 arthritis Diseases 0.000 claims description 3
208000006673 asthma Diseases 0.000 claims description 3
201000008937 atopic dermatitis Diseases 0.000 claims description 3
230000000747 cardiac effect Effects 0.000 claims description 3
208000024908 graft versus host disease Diseases 0.000 claims description 3
238000006396 nitration reaction Methods 0.000 claims description 3
230000036303 septic shock Effects 0.000 claims description 3
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
206010052779 Transplant rejections Diseases 0.000 claims 1
125000002490 anilino group Chemical class [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
125000005843 halogen group Chemical group 0.000 claims 1
102000004890 Interleukin-8 Human genes 0.000 description 58
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 56
229940096397 interleukin-8 Drugs 0.000 description 56
210000004027 cell Anatomy 0.000 description 23
101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 description 22
101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 22
102100036154 Platelet basic protein Human genes 0.000 description 22
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 16
210000000440 neutrophil Anatomy 0.000 description 16
102100034221 Growth-regulated alpha protein Human genes 0.000 description 15
101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 15
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 13
108060008682 Tumor Necrosis Factor Proteins 0.000 description 13
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 13
230000014509 gene expression Effects 0.000 description 13
102000005962 receptors Human genes 0.000 description 13
108020003175 receptors Proteins 0.000 description 13
101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
239000000243 solution Substances 0.000 description 12
-1 IL-1α Proteins 0.000 description 11
108020004999 messenger RNA Proteins 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 10
230000006378 damage Effects 0.000 description 10
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 9
102000004127 Cytokines Human genes 0.000 description 9
108090000695 Cytokines Proteins 0.000 description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
210000004556 brain Anatomy 0.000 description 9
208000014674 injury Diseases 0.000 description 9
239000007787 solid Substances 0.000 description 9
239000002904 solvent Substances 0.000 description 9
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 8
102000000589 Interleukin-1 Human genes 0.000 description 8
108010002352 Interleukin-1 Proteins 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
208000027418 Wounds and injury Diseases 0.000 description 8
208000029028 brain injury Diseases 0.000 description 8
230000035605 chemotaxis Effects 0.000 description 8
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
239000007788 liquid Substances 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
235000019439 ethyl acetate Nutrition 0.000 description 6
239000012530 fluid Substances 0.000 description 6
102000010681 interleukin-8 receptors Human genes 0.000 description 6
108010038415 interleukin-8 receptors Proteins 0.000 description 6
210000002540 macrophage Anatomy 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
238000005160 1H NMR spectroscopy Methods 0.000 description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
102000016387 Pancreatic elastase Human genes 0.000 description 5
108010067372 Pancreatic elastase Proteins 0.000 description 5
230000004913 activation Effects 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
150000002391 heterocyclic compounds Chemical class 0.000 description 5
238000009527 percussion Methods 0.000 description 5
239000013641 positive control Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 4
102000004889 Interleukin-6 Human genes 0.000 description 4
108090001005 Interleukin-6 Proteins 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
102100040247 Tumor necrosis factor Human genes 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic acid anhydride Natural products CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 4
102000012740 beta Adrenergic Receptors Human genes 0.000 description 4
108010079452 beta Adrenergic Receptors Proteins 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
238000007796 conventional method Methods 0.000 description 4
210000002889 endothelial cell Anatomy 0.000 description 4
230000006870 function Effects 0.000 description 4
210000001320 hippocampus Anatomy 0.000 description 4
230000008595 infiltration Effects 0.000 description 4
238000001764 infiltration Methods 0.000 description 4
230000002757 inflammatory effect Effects 0.000 description 4
229940100601 interleukin-6 Drugs 0.000 description 4
238000007912 intraperitoneal administration Methods 0.000 description 4
239000006210 lotion Substances 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
230000001936 parietal effect Effects 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
230000009467 reduction Effects 0.000 description 4
230000004044 response Effects 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
210000003491 skin Anatomy 0.000 description 4
VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 4
238000012360 testing method Methods 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
229910021626 Tin(II) chloride Inorganic materials 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
230000000844 anti-bacterial effect Effects 0.000 description 3
239000003899 bactericide agent Substances 0.000 description 3
210000003651 basophil Anatomy 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000002975 chemoattractant Substances 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000000203 mixture Substances 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
230000011242 neutrophil chemotaxis Effects 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
239000000523 sample Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
235000011150 stannous chloride Nutrition 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
229910052725 zinc Inorganic materials 0.000 description 3
SWEICGMKXPNXNU-UHFFFAOYSA-N 1,2-dihydroindazol-3-one Chemical compound C1=CC=C2C(O)=NNC2=C1 SWEICGMKXPNXNU-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
235000003911 Arachis Nutrition 0.000 description 2
244000105624 Arachis hypogaea Species 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
101500025785 Homo sapiens IL-8(6-77) Proteins 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
102400001232 IL-8(6-77) Human genes 0.000 description 2
108010074338 Lymphokines Proteins 0.000 description 2
102000008072 Lymphokines Human genes 0.000 description 2
102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
102000013967 Monokines Human genes 0.000 description 2
108010050619 Monokines Proteins 0.000 description 2
108010025020 Nerve Growth Factor Proteins 0.000 description 2
102000015336 Nerve Growth Factor Human genes 0.000 description 2
238000000636 Northern blotting Methods 0.000 description 2
241000700159 Rattus Species 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
208000030886 Traumatic Brain injury Diseases 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
150000001448 anilines Chemical class 0.000 description 2
239000000010 aprotic solvent Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000003399 chemotactic effect Effects 0.000 description 2
239000006071 cream Substances 0.000 description 2
238000011161 development Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000000417 fungicide Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
238000007429 general method Methods 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
230000003394 haemopoietic effect Effects 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
230000028993 immune response Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
239000012948 isocyanate Substances 0.000 description 2
239000000865 liniment Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
CMEUDEVBFFPSEI-NFHWZJRKSA-N methyl 4-[[(2s)-1-[[(2s)-1-[(2s)-2-[[(2s)-3-methyl-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoate Chemical compound COC(=O)CCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NC1=CC=C(C(C)=CC(=O)O2)C2=C1 CMEUDEVBFFPSEI-NFHWZJRKSA-N 0.000 description 2
239000013642 negative control Substances 0.000 description 2
229940053128 nerve growth factor Drugs 0.000 description 2
230000003448 neutrophilic effect Effects 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000006072 paste Substances 0.000 description 2
229960001412 pentobarbital Drugs 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
229920000515 polycarbonate Polymers 0.000 description 2
239000004417 polycarbonate Substances 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
239000000843 powder Substances 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
238000001525 receptor binding assay Methods 0.000 description 2
235000010344 sodium nitrate Nutrition 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
229940124530 sulfonamide Drugs 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000010189 synthetic method Methods 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
230000000472 traumatic effect Effects 0.000 description 2
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
239000011701 zinc Substances 0.000 description 2
LOGLVGABKVIWBC-UHFFFAOYSA-N (2-chlorophenyl)methanesulfonamide Chemical compound NS(=O)(=O)CC1=CC=CC=C1Cl LOGLVGABKVIWBC-UHFFFAOYSA-N 0.000 description 1
FUEFNUGYRWQHTH-UHFFFAOYSA-N (2-nitrophenyl)methanesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC=C1CS(Cl)(=O)=O FUEFNUGYRWQHTH-UHFFFAOYSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
VVAKEQGKZNKUSU-UHFFFAOYSA-N 2,3-dimethylaniline Chemical compound CC1=CC=CC(N)=C1C VVAKEQGKZNKUSU-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
102000040717 Alpha family Human genes 0.000 description 1
108091071248 Alpha family Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229910000761 Aluminium amalgam Inorganic materials 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
239000007989 BIS-Tris Propane buffer Substances 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 description 1
GWEHVDNNLFDJLR-UHFFFAOYSA-N Carbanilide Natural products C=1C=CC=CC=1NC(=O)NC1=CC=CC=C1 GWEHVDNNLFDJLR-UHFFFAOYSA-N 0.000 description 1
102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
208000018652 Closed Head injury Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101100441523 Homo sapiens CXCL5 gene Proteins 0.000 description 1
101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
101000818522 Homo sapiens fMet-Leu-Phe receptor Proteins 0.000 description 1
101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102100025390 Integrin beta-2 Human genes 0.000 description 1
102100039065 Interleukin-1 beta Human genes 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010029113 Neovascularisation Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229920003171 Poly (ethylene oxide) Chemical class 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
210000000662 T-lymphocyte subset Anatomy 0.000 description 1
GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
210000001056 activated astrocyte Anatomy 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
239000003708 ampul Substances 0.000 description 1
238000001949 anaesthesia Methods 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
239000012300 argon atmosphere Substances 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
210000001130 astrocyte Anatomy 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000004271 bone marrow stromal cell Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
230000036978 cell physiology Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
239000005482 chemotactic factor Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
229960002152 chlorhexidine acetate Drugs 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000012954 diazonium Substances 0.000 description 1
150000001989 diazonium salts Chemical class 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000006196 drop Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000005175 epidermal keratinocyte Anatomy 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
102100021145 fMet-Leu-Phe receptor Human genes 0.000 description 1
238000010265 fast atom bombardment Methods 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000003292 glue Substances 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
239000011539 homogenization buffer Substances 0.000 description 1
239000003906 humectant Substances 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
239000011147 inorganic material Substances 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
108010019677 lymphotactin Proteins 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
229940071648 metered dose inhaler Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
229920001206 natural gum Polymers 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
ZAQDQFFQEKUULQ-UHFFFAOYSA-N nitrooxy(phenyl)mercury;phenylmercury;hydrate Chemical compound O.[Hg]C1=CC=CC=C1.[O-][N+](=O)O[Hg]C1=CC=CC=C1 ZAQDQFFQEKUULQ-UHFFFAOYSA-N 0.000 description 1
GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000009719 regenerative response Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000019254 respiratory burst Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
230000035939 shock Effects 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000000344 soap Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000004317 sodium nitrate Substances 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
ULTYUQKPJIIHLU-UHFFFAOYSA-M sodium;(2-aminophenyl)methanesulfonate Chemical compound [Na+].NC1=CC=CC=C1CS([O-])(=O)=O ULTYUQKPJIIHLU-UHFFFAOYSA-M 0.000 description 1
239000002689 soil Substances 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000009529 traumatic brain injury Effects 0.000 description 1
FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
150000003672 ureas Chemical class 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
239000001993 wax Substances 0.000 description 1
210000002268 wool Anatomy 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Thiazole And Isothizaole Compounds (AREA)
Indole Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

NO19993585A 1997-01-23 1999-07-22 IL-8 reseptor antagonister, anvendelse og fremgangsmÕte for fremstilling derav, samt farmasöytisk preparat NO313913B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US3599097P	1997-01-23	1997-01-23
US4283097P	1997-04-08	1997-04-08
PCT/US1998/001292 WO1998032438A1 (en)	1997-01-23	1998-01-23	Il-8 receptor antagonists

Publications (3)

Publication Number	Publication Date
NO993585D0 NO993585D0 (no)	1999-07-22
NO993585L NO993585L (no)	1999-09-21
NO313913B1 true NO313913B1 (no)	2002-12-23

Family

ID=26712686

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19993585A NO313913B1 (no)	1997-01-23	1999-07-22	IL-8 reseptor antagonister, anvendelse og fremgangsmÕte for fremstilling derav, samt farmasöytisk preparat

Country Status (20)

Country	Link
US (1)	US6166055A (es)
EP (1)	EP1005341B1 (es)
JP (1)	JP2002515055A (es)
KR (1)	KR20000070369A (es)
CN (1)	CN1253501A (es)
AR (1)	AR008331A1 (es)
AT (1)	ATE381330T1 (es)
AU (1)	AU729893B2 (es)
BR (1)	BR9807085A (es)
CA (1)	CA2278427A1 (es)
DE (1)	DE69838874T2 (es)
ES (1)	ES2299200T3 (es)
HU (1)	HUP0001940A3 (es)
IL (1)	IL131005A0 (es)
NO (1)	NO313913B1 (es)
NZ (1)	NZ336859A (es)
PE (1)	PE103699A1 (es)
PL (1)	PL334774A1 (es)
TR (1)	TR199901761T2 (es)
WO (1)	WO1998032438A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5929250A (en) *	1997-01-23	1999-07-27	Smithkline Beecham Corporation	IL-8 receptor antagonists
AR015426A1 (es) *	1997-09-05	2001-05-02	Smithkline Beecham Corp	Compuestos de benzotiazol antagonistas del receptor de il-8, composicion farmaceutica que los contiene, su uso para la manufactura de un medicamento,procedimiento para su preparacion, compuestos intermediarios y procedimiento para su preparacion
AR015425A1 (es) *	1997-09-05	2001-05-02	Smithkline Beecham Corp	Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion
WO2000021963A1 (en) *	1998-10-13	2000-04-20	Smithkline Beecham Corporation	Il-8 receptor antagonists
WO2000069435A1 (en) *	1999-05-18	2000-11-23	Smithkline Beecham Corporation	Il-8 receptor antagonists
KR20020030786A (ko) *	1999-07-16	2002-04-25	스타르크, 카르크	치환 벤즈이소티아졸 화합물의 제조 방법
US6440993B1 (en)	1999-10-12	2002-08-27	Smithkline Beecham Corporation	IL-8 receptor antagonists
PE20011124A1 (es)	2000-03-31	2001-10-28	Upjohn Co	Nuevos agentes antibacterianos de benzosultam oxazolidinona
DE10038709A1 (de)	2000-08-09	2002-02-28	Aventis Pharma Gmbh	Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
GB0403038D0 (en)	2004-02-11	2004-03-17	Novartis Ag	Organic compounds
US7326729B2 (en)	2004-05-12	2008-02-05	Schering Corporation	CXCR1 and CXCR2 chemokine antagonists
AR065369A1 (es)	2007-02-19	2009-06-03	Novartis Ag	Derivados de ciclohexil - amida del acido aril- carboxilico
SG11201407402TA (en)	2012-05-11	2014-12-30	Reset Therapeutics Inc	Carbazole-containing sulfonamides as cryptochrome modulators
TWI690521B (zh)	2014-04-07	2020-04-11	美商同步製藥公司	作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5795887A (en) *	1994-04-15	1998-08-18	Glaxo Wellcome Inc.	Method of inducing cholecystokinin agonist activity using 1,4- Benzodiazepine compounds
JP3720395B2 (ja) *	1994-09-20	2005-11-24	京都薬品工業株式会社	新規ヘテロ環誘導体、その製造方法およびその医薬用途
KR100388345B1 (ko) *	1995-10-05	2004-03-30	교토 야쿠힝 고교 가부시키가이샤	신규헤테로시클릭유도체및이것의의약용도
US5929250A (en) *	1997-01-23	1999-07-27	Smithkline Beecham Corporation	IL-8 receptor antagonists
AR015426A1 (es) *	1997-09-05	2001-05-02	Smithkline Beecham Corp	Compuestos de benzotiazol antagonistas del receptor de il-8, composicion farmaceutica que los contiene, su uso para la manufactura de un medicamento,procedimiento para su preparacion, compuestos intermediarios y procedimiento para su preparacion
AR015425A1 (es) *	1997-09-05	2001-05-02	Smithkline Beecham Corp	Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion
AU2234199A (en) *	1998-01-16	1999-08-02	Smithkline Beecham Corporation	Il-8 receptor antagonists

1998
- 1998-01-22 AR ARP980100284A patent/AR008331A1/es not_active Application Discontinuation
- 1998-01-23 CA CA002278427A patent/CA2278427A1/en not_active Abandoned
- 1998-01-23 DE DE69838874T patent/DE69838874T2/de not_active Expired - Fee Related
- 1998-01-23 TR TR1999/01761T patent/TR199901761T2/xx unknown
- 1998-01-23 CN CN98803564A patent/CN1253501A/zh active Pending
- 1998-01-23 EP EP98901852A patent/EP1005341B1/en not_active Expired - Lifetime
- 1998-01-23 WO PCT/US1998/001292 patent/WO1998032438A1/en not_active Ceased
- 1998-01-23 US US09/341,382 patent/US6166055A/en not_active Expired - Fee Related
- 1998-01-23 JP JP53213998A patent/JP2002515055A/ja not_active Ceased
- 1998-01-23 PL PL98334774A patent/PL334774A1/xx unknown
- 1998-01-23 KR KR1019997006602A patent/KR20000070369A/ko not_active Ceased
- 1998-01-23 AU AU58278/98A patent/AU729893B2/en not_active Ceased
- 1998-01-23 IL IL13100598A patent/IL131005A0/xx unknown
- 1998-01-23 ES ES98901852T patent/ES2299200T3/es not_active Expired - Lifetime
- 1998-01-23 AT AT98901852T patent/ATE381330T1/de not_active IP Right Cessation
- 1998-01-23 HU HU0001940A patent/HUP0001940A3/hu unknown
- 1998-01-23 NZ NZ336859A patent/NZ336859A/xx unknown
- 1998-01-23 BR BR9807085-1A patent/BR9807085A/pt not_active Application Discontinuation
- 1998-07-22 PE PE1998000656A patent/PE103699A1/es not_active Application Discontinuation
1999
- 1999-07-22 NO NO19993585A patent/NO313913B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP1005341B1 (en)	2007-12-19
ATE381330T1 (de)	2008-01-15
CA2278427A1 (en)	1998-07-30
DE69838874D1 (de)	2008-01-31
EP1005341A4 (en)	2004-09-08
JP2002515055A (ja)	2002-05-21
NO993585D0 (no)	1999-07-22
KR20000070369A (ko)	2000-11-25
IL131005A0 (en)	2001-01-28
AU5827898A (en)	1998-08-18
PE103699A1 (es)	1999-12-30
AR008331A1 (es)	1999-12-29
DE69838874T2 (de)	2008-12-04
HUP0001940A3 (en)	2002-09-30
CN1253501A (zh)	2000-05-17
NZ336859A (en)	2001-01-26
US6166055A (en)	2000-12-26
WO1998032438A1 (en)	1998-07-30
BR9807085A (pt)	2000-04-18
EP1005341A1 (en)	2000-06-07
ES2299200T3 (es)	2008-05-16
TR199901761T2 (xx)	1999-10-21
HUP0001940A2 (hu)	2001-01-29
AU729893B2 (en)	2001-02-15
NO993585L (no)	1999-09-21
PL334774A1 (en)	2000-03-13

Publication	Publication Date	Title
US6300325B1 (en)	2001-10-09	IL-8 receptor antagonists
US6271261B1 (en)	2001-08-07	IL-8 receptor antagonists
US6218539B1 (en)	2001-04-17	IL-8 receptor antagonists
US6133319A (en)	2000-10-17	IL-8 receptor antagonists
US5929250A (en)	1999-07-27	IL-8 receptor antagonists
US6204294B1 (en)	2001-03-20	IL-8 receptor antagonists
US6214881B1 (en)	2001-04-10	IL-8 receptor antagonists
JP2004520412A (ja)	2004-07-08	Ｉｌ−８受容体アンタゴニスト
NO313913B1 (no)	2002-12-23	IL-8 reseptor antagonister, anvendelse og fremgangsmÕte for fremstilling derav, samt farmasöytisk preparat
EP1261328B1 (en)	2005-07-20	Il-8 receptor antagonists
EP1180028B1 (en)	2007-01-24	Il-8 receptor antagonists
EP0971908B1 (en)	2004-06-30	Il-8 receptor antagonists
US6335352B1 (en)	2002-01-01	IL-8 receptor antagonists
US6248785B1 (en)	2001-06-19	IL-8 receptor antagonists
US6436927B1 (en)	2002-08-20	IL-8 receptor antagonists
US6177448B1 (en)	2001-01-23	IL-8 receptor antagonists
US6221889B1 (en)	2001-04-24	IL-8 receptor antagonists
US6440993B1 (en)	2002-08-27	IL-8 receptor antagonists
US20030032802A1 (en)	2003-02-13	IL8-receptor antagonists
US20030225125A1 (en)	2003-12-04	IL-8 receptor antagonists
WO2000073282A1 (en)	2000-12-07	Il-8 receptor antagonists
WO2000069435A1 (en)	2000-11-23	Il-8 receptor antagonists
CZ257899A3 (cs)	2000-02-16	Antagonista receptorů interleukinu IL-8
MXPA01000822A (es)	2001-09-07	Antagonistas de receptor il-8
CA2335292A1 (en)	1999-12-23	Il-8 receptor antagonists

Legal Events

Date	Code	Title	Description
2004-12-13	MM1K	Lapsed by not paying the annual fees